[{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Oxford Nanopore Technologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Oxford Nanopore Technologies","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Oxford Nanopore Technologies"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Sosei Group Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MOLCURE Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ MOLCURE Inc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MOLCURE Inc"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Neogene"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Seismic Bio"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MediSix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ MediSix","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MediSix"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Artisan Industries Inc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Artisan Industries Inc"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Nkarta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Nkarta","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Nkarta"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Invetx","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Invetx"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Abcam plc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Abcam plc"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Twist Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Twist Bioscience"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TB202-3","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Proteona"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Twist Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : PBA-0405 is a novel ROR1 Inhibitor antibody with significantly improved therapeutic properties, which is currently being evaluated for the treatment of HNSCC.

                          Product Name : PBA-0405

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          July 18, 2024

                          Lead Product(s) : PBA-0405

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The collaboration aims to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Oxford Nanopore Technologies

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options, identified by Astellas.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          September 01, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against targets identified by Ono for the treatment of autoimmune diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 31, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the agreement, Twist Biopharma, will leverage its Library of Libraries to conduct antibody discovery campaigns against targets to be determined by Bayer. Bayer will have the option to license antibodies discovered under the collaboration.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Bayer AG

                          Deal Size : $188.0 million

                          Deal Type : Agreement

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the collaboration, Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 20, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Alpaca-derived VHH antibody is a heavy chain antibody fragment (VHH), anti-SARS-CoV-2 nanobody (saRBD-1), that disrupts spike glycoprotein of SARS-CoV-2 interaction with human ACE 2 by competitively binding to the spike protein receptor-binding domain.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Twist intends to use the net proceeds of the offering, along with its existing cash, cash equivalents and short-term investments to scale its investment in its research and development organization, which includes investing in pharmaceutical biologics dr...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 02, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : J.P. Morgan Securities LLC

                          Deal Size : $250.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary Twist antagonist antibodies, targeting an undisclosed checkpoint inhibitor pathway in the tumor microenvironment, as potential t...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the collaboration, Twist will leverage its proprietary Library of Libraries to discover 5 novel antibodies. MediSix will use its platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 04, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : MediSix

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank